Section Arrow
Quote
TNXP.NASDAQ
- Tonix Pharmaceuticals Holding Corp
Quotes are at least 15-min delayed:2025/07/21 06:42 EDT
Pre Market
Last
 48.25
+1.34 (+2.86%)
Bid
48.2
Ask
48.5
High 49.94 
Low 45.7 
Volume 6914 
Regular Hours
Last
 46.91
-0.28 (-0.59%)
Day High 
48.795 
Prev. Close
47.19 
1-M High
50.3999 
Volume 
1.49M 
Bid
48.2
Ask
48.5
Day Low
45.5 
Open
48.74 
1-M Low
30.82 
Market Cap 
347.19M 
Currency USD 
P/E 0.13 
%Yield -- 
10-SMA 40.73 
20-SMA 37.77 
50-SMA 33.8 
52-W High 130 
52-W Low 6.76 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
356.28/-5.99
Enterprise Value
352.21M
Balance Sheet
Book Value Per Share
24.52
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
10.09M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2 -0.28 -12.28%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.13 -0.945 -6.71%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0474 -0.0003 -0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.22 +0.38 +6.51%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.06 +0.14 +2.36%
Quotes are at least 15-min delayed：2025/07/21 06:42 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targetingCD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.